An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis.
about
Oligonucleotide therapeutic approaches for Huntington diseaseTNF-{alpha} plays a role in hepatocyte apoptosis in Niemann-Pick type C liver diseaseNew therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugsAn Exocyclic Methylene Group Acts As a Bioisostere of the 2′-Oxygen Atom in LNAAntisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic miceEvaluation of an anti-tumor necrosis factor therapeutic in a mouse model of Niemann-Pick C liver diseaseSilencing disease genes in the laboratory and the clinicAntisense oligonucleotide-induced alternative splicing of the APOB mRNA generates a novel isoform of APOB.Chemical modification: the key to clinical application of RNA interference?Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia.Apolipoprotein B100 quality control and the regulation of hepatic very low density lipoprotein secretion.Recovery from liver disease in a Niemann-Pick type C mouse model.CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance.Therapeutic RNA manipulation in liver disease.Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primatesPrelamin A and lamin A appear to be dispensable in the nuclear lamina.Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (kynamro(®)): a second-generation antisense oligonucleotide inhibitor of apolipoprotein BLDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectivesSpecific reduction of hepatic glucose 6-phosphate transporter-1 ameliorates diabetes while avoiding complications of glycogen storage disease.Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice.Evolving targets for lipid-modifying therapysiRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipidsC-reactive protein and atherogenesis: new insights from established animal models.Antisense oligonucleotide induction of progerin in human myogenic cellsApoB siRNA-induced liver steatosis is resistant to clearance by the loss of fatty acid transport protein 5 (Fatp5)Insulin resistance induces posttranslational hepatic sortilin 1 degradation in mice.CGI-58/ABHD5-derived signaling lipids regulate systemic inflammation and insulin action.Protein disulfide isomerases contribute differentially to the endoplasmic reticulum-associated degradation of apolipoprotein B and other substratesAntisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteinsGene therapy for dyslipidemia: a review of gene replacement and gene inhibition strategiesReduction of TIP47 improves hepatic steatosis and glucose homeostasis in miceDynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes.Regulation of inflammatory arthritis by the upstream kinase mitogen activated protein kinase kinase 7 in the c-Jun N-terminal kinase pathwayAntisense oligonucleotides as therapeutics for hyperlipidaemias.A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and HumansEmbedding siRNA sequences targeting apolipoprotein B100 in shRNA and miRNA scaffolds results in differential processing and in vivo efficacyEffects of pyrazole partial agonists on HCA(2) -mediated flushing and VLDL-triglyceride levels in mice.TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice.In vivo antisense oligonucleotide reduction of NPC1 expression as a novel mouse model for Niemann Pick type C- associated liver disease.ISIS 301012 gene therapy for hypercholesterolemia: sense, antisense, or nonsense?
P2860
Q22306293-249B8028-18DB-4B8D-A12D-579AB02229C9Q24657208-A4F46084-586A-4EB0-8CEF-92FFB32DF193Q26863369-6D8B045F-1171-4C4D-8AD9-DB23DEC25EE3Q27664845-010E8A04-B782-4108-9A22-CCECA7780DF4Q28588849-DF36DC1A-0003-4236-8124-475F4BCA6633Q28749178-BE6A30A3-36CA-4C85-9A2C-8283873FA71CQ29039090-D228A8AD-E723-4FAA-99C1-AF6972E84335Q33269609-1CF9603A-55D7-46D4-A6DF-B6F89479AE91Q33308712-152C7615-12E9-4091-BE36-0351F7FF4119Q33784492-AF84059F-EED9-4712-A5B5-F8790E20BAFAQ33858526-F9A6FB1D-F6FC-45A1-94B1-4EF5CDF1133BQ33993252-B4CCE405-BC42-4BC2-9639-7DCDF8193634Q34188075-0E1AE011-B819-4BFE-8F74-9536D4A77978Q34244756-2C165E4D-5DCB-45BA-9954-0719C62E0AD7Q34298059-37BE3CCB-01F8-40FC-AE95-31BDB3388AE1Q34416396-3BDB5F2B-218A-431D-A830-69514D77718FQ34456562-D3E00FB5-2C5E-494D-B2DD-2A08A230FEA3Q34467839-08207F7B-F988-4DE0-ABF2-4DB9DC2755E3Q34654019-C42C5E2F-F0E3-4C51-A8D5-DCC7370623DAQ34776352-CAD793EA-7599-4863-B906-C640C4FA2217Q34880292-B7047E2F-0F39-43C8-A7FF-561060E9F538Q34955791-00788294-4B4B-4620-8D64-D1EC830D508EQ35085254-15816B4E-8E5A-4593-87C1-E350E15F30AAQ35180565-76625E33-D9C8-4581-B300-051BF49B15A5Q35541914-2A4BF9C0-8CAF-412C-9D32-F21DC95E6CDEQ35561045-1604CA11-D9D1-42E1-86C6-14371B570ADAQ35696460-043239B6-61A5-42C3-A671-8B92130E211DQ35756661-86EA7BE1-42F6-4D30-9411-B40C25518DBBQ35839701-621AF061-D1BF-4A25-9934-CA84E1CA967CQ35884548-9CF62DD7-2C38-4EF6-95E7-A37C1FEB175AQ35900825-55FB18E1-E2D3-40A2-ADE6-0207C9E58D7CQ35928850-B60E1D93-22F3-4614-821A-D40FD8EA91AFQ36085047-6311F277-5BEF-4242-913F-49C44CBB9161Q36194069-CA6A1FA1-CD0C-4915-9CDC-CD75A9D74350Q36438294-E426F9FD-4C19-42C0-8154-A4E3A240DF35Q36512514-3BC13B9C-6F8A-4DAA-ABEC-898D306AEBBBQ36619771-AC3F09C3-CCB5-46E7-9B97-0B5E0AC64021Q36633583-CE66ECE1-031C-4628-A830-6A7D953365EFQ36736837-A7268304-BC84-46EB-B510-2E5AC9AEBD34Q36937561-CAE0EBAE-D3B7-4D9A-BC68-59D59093A610
P2860
An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
An apolipoprotein B antisense ...... out causing hepatic steatosis.
@en
An apolipoprotein B antisense ...... out causing hepatic steatosis.
@nl
type
label
An apolipoprotein B antisense ...... out causing hepatic steatosis.
@en
An apolipoprotein B antisense ...... out causing hepatic steatosis.
@nl
prefLabel
An apolipoprotein B antisense ...... out causing hepatic steatosis.
@en
An apolipoprotein B antisense ...... out causing hepatic steatosis.
@nl
P2093
P2860
P1476
An apolipoprotein B antisense ...... out causing hepatic steatosis.
@en
P2093
Charles P Whipple
Kristina M Lemonidis
Mark J Graham
Ranjan J Perera
Rosanne M Crooke
Seonjoon Koo
P2860
P304
P356
10.1194/JLR.M400492-JLR200
P577
2005-02-16T00:00:00Z